ARCA biopharma (NASDAQ:ABIO – Get Free Report) was upgraded by stock analysts at StockNews.com to a “sell” rating in a research note issued to investors on Tuesday.
ARCA biopharma Price Performance
ARCA biopharma stock traded up $0.09 during trading hours on Tuesday, reaching $3.67. The company had a trading volume of 176,991 shares, compared to its average volume of 611,378. The firm has a market cap of $53.24 million, a price-to-earnings ratio of -8.74 and a beta of 0.91. ARCA biopharma has a 12-month low of $1.56 and a 12-month high of $4.49. The company has a 50-day moving average price of $3.26 and a 200 day moving average price of $2.83.
Insider Buying and Selling at ARCA biopharma
In other ARCA biopharma news, major shareholder Henderson Group Plc Janus bought 189,856 shares of the firm’s stock in a transaction on Wednesday, July 24th. The stock was acquired at an average price of $3.20 per share, with a total value of $607,539.20. Following the completion of the purchase, the insider now owns 2,081,168 shares of the company’s stock, valued at $6,659,737.60. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. In the last three months, insiders have bought 492,997 shares of company stock valued at $1,667,418. 30.90% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On ARCA biopharma
About ARCA biopharma
ARCA biopharma, Inc, a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure.
Read More
- Five stocks we like better than ARCA biopharma
- What is a Stock Market Index and How Do You Use Them?
- Columbia Sportswear: A Turnaround Story That’s Gaining Ground
- What Are the FAANG Stocks and Are They Good Investments?
- Lowe’s Stock: Hold Now, Buy it When it Dips
- Are Penny Stocks a Good Fit for Your Portfolio?
- ZIM Shipping Stock Soars as the Industry Shows a Bottoming Trend
Receive News & Ratings for ARCA biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARCA biopharma and related companies with MarketBeat.com's FREE daily email newsletter.